确定脓毒性休克逆转在随机分配至早期目标导向限制液体策略与常规治疗的儿科患者中是否更快的试验(SQUEEZE):一项先导随机对照试验的研究方案
SQUEEZE先导试验为务实、两臂、平行分组、开放标签、前瞻性先导随机对照试验,纳入29天至18岁以下疑似或确诊脓毒性休克且需持续复苏的儿童,在豁免同意程序下随机分配至常规治疗或限制液体复苏策略,主要目标是评估入组率和方案依从性等可行性,主要结局指标为入组率(每中心每月至少2例为通过)。
要点
- SQUEEZE先导试验主要评估在儿科脓毒性休克中开展限制液体策略随机对照试验的可行性。
- 主要结局为入组率,通过标准为每中心每月至少入组2例。
- 将评估基线及24小时血样中游离DNA描述的可行性以支持嵌套转化研究SQUEEZE-D。
核心结论
- 该先导试验旨在确定在儿科脓毒性休克患者中比较早期目标导向限制液体策略与常规治疗的可行性,研究结果将为计划中的多中心试验提供可行性依据。
研究设计与样本
- SQUEEZE先导试验为务实、两臂、平行分组、开放标签、前瞻性先导随机对照试验。
- 参与者为29天至18岁以下疑似或确诊脓毒性休克且需要持续复苏的儿童,在豁免同意程序下入组并通过隐蔽分配随机分至常规治疗(对照)或限制液体(干预)复苏策略。
主要发现
- 主要结局指标为入组率,通过标准定义为每中心每月至少2例,并认识到导入期入组可能较慢。
- 次要目标包括评估入选标准的适当性和临床结局的完整性,以为计划中的多中心试验确定终点。
- 将评估在基线及24小时采集的入组儿童血样中描述游离DNA(一种具有预后价值的促凝血分子)的可行性,以支持嵌套转化研究SQUEEZE-D。
关键数值与推荐
- 入组率通过标准为每中心每月至少2例。
- SQUEEZE先导试验招募于2014年1月6日开放。
- 试验注册号为ClinicalTrials.gov NCT01973907,注册于2013年10月23日。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出在开始血管活性支持前儿科脓毒性休克早期复苏所需的最佳血管内液体量仍未得到解答。
- 原文指出为实现推荐治疗目标所需的最佳液体复苏程度和血管活性支持启动时机在脓毒性休克儿童中仍未得到解答。
- 原文指出迄今为止尚无前瞻性研究在包括加拿大在内的发达国家儿童中探讨这一重要问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current pediatric septic shock resuscitation guidelines from the American College of Critical Care Medicine focus on the early and goal-directed administration of intravascular fluid followed by vasoactive medication infusions for persistent and fluid-refractory shock. However, accumulating adult and pediatric data suggest that excessive fluid administration is associated with worse patient outcomes and even increased risk of death. The optimal amount of intravascular fluid required in early pediatric septic shock resuscitation prior to the initiation of vasoactive support remains unanswered. METHODS/DESIGN: The SQUEEZE Pilot Trial is a pragmatic, two-arm, parallel-group, open-label, prospective pilot randomized controlled trial. Participants are children aged 29 days to under 18 years with suspected or confirmed septic shock and a need for ongoing resuscitation. Eligible participants are enrolled under an exception to consent process and randomly assigned via concealed allocation to either the Usual Care (control) or Fluid Sparing (intervention) resuscitation strategy. The primary objective of this pilot trial is to determine feasibility, based on the ability to enroll participants and to adhere to the study protocol. The primary outcome measure by which success will be determined is participant enrollment rate ("pass" defined as at least two participants/site/month, recognizing that enrollment may be slower during the run-in phase). Secondary objectives include assessing (1) appropriateness of eligibility criteria, and (2) completeness of clinical outcomes to inform the endpoints for the planned multisite trial. To support the nested translational study, SQUEEZE-D, we will also evaluate the feasibility of describing cell-free DNA (a procoagulant molecule with prognostic utility) in blood samples obtained from children enrolled into the SQUEEZE Pilot Trial at baseline and at 24 h. DISCUSSION: The optimal degree of fluid resuscitation and the timing of initiation of vasoactive support in order to achieve recommended therapeutic targets in children with septic shock remains unanswered. No prospective study to date has examined this important question for children in developed countries including Canada. Recruitment for the SQUEEZE Pilot Trial opened on 6 January 2014. Findings will inform the feasibility of the planned multicenter trial to answer our overall research question. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT01973907 , registered on 23 October 2013.
引用
- Parker MJ, Thabane L, Fox-Robichaud A, et al. A trial to determine whether septic shock-reversal is quicker in pediatric patients randomized to an early goal-directed fluid-sparing strategy versus usual care (SQUEEZE): study protocol for a pilot randomized controlled trial. Trials. 2016. PMID: 27876084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。